



Post Authorisation Assessments

For details of post authorisation assessments prior to 1st January 2021, please refer to the [EMA](#) website.

Bravecto 1,000 mg Chewable Tablets for Large Dogs (>20 – 40 kg)

• 18 November 2022	<p>The grouped variation is to add two new therapeutic indications for Bravecto chewable tablets for dogs: for persistent tick killing activity from 7 days to 12 weeks after treatment for Ixodes hexagonus and for reduction of the risk of infection with Dipylidium caninum via transmission by Ctenocephalides felis for up to 12 weeks.</p> <p>The grouped variation is to add two new therapeutic indications for Bravecto chewable tablets for dogs: for persistent tick killing activity from 7 days to 12 weeks after treatment for Ixodes hexagonus and for reduction of the risk of infection with Dipylidium caninum via transmission by Ctenocephalides felis for up to 12 weeks</p>
• 02 August 2022	To add an alternative irradiation test method for the pork liver flavour excipient from the SPF supplier used in Bravecto chewable tablets.
• 23 June 2022	Change in name of manufacturer of the active substance.
• 20 April 2022	Introduction of an alternative manufacturer of an excipient.
• 04 February 2022	Addition of a new therapeutic indication
• 21 December 2021	Change in the specification limits of an excipient.
• 03 September 2021	Changes to the labelling and/or package leaflet.